Arrowhead Research Corporation — チャート、価格、ニュース (NASDAQ:ARWR)

チャート全体を表示

Financials

概要明細書統計

期次年次

Market Capitalization 9.4032 B
Employee 711
Founded 2004
CEO Christopher Richard Anzalone
Website www.arrowheadpharma.com
Headquarter Delaware, United States
FIGI BBG000BRVKH0
Industry Technology

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

9.4 B 時価総額

株価収益率

-3 449

売上高対価格比率

5.56

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals Inc

ニュース

Wave Life Sciences Crashes 55% As 'Body Composition' Fat-Loss Drug Underwhelms

Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Arrowhead Pharmaceuticals最高医療責任者が64万1900ドル相当の株式を売却

Arrowhead PharmaceuticalsがLeerinkカンファレンスで戦略的パイプライン見通しを提示

Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights

アローヘッド・ファーマシューティカルズ、TD Cowenカンファレンスで心臓代謝領域への戦略的注力を表明

Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

Sarepta第4四半期決算：売上高は予想上回るも収益性への道筋示す

GSK Strikes $1 Billion China RNA Deal